Introduction
============

A total of 56.4 million deaths occurred globally in 2015, of which non-communicable diseases (NCDs) were responsible for 39.5 million cases (70%) and 30.7 million cases occurred in low- and middle-income countries, for which approximately 48% of the deaths took place before the age of 70. Of these NCD death cases, cardiovascular diseases (CVDs) were responsible for 17.7 million (45%) of the deaths ([@B74], [@B75]). Based on data from the World Health Organization (WHO), the total annual number of deaths from NCDs is projected to increase to 52 million by 2030 ([@B74]). The most well-known risk factors for CVDs include elevated blood pressure, smoking, high cholesterol and blood glucose level, poor diet, obesity, and risky use of alcohol ([@B73], [@B74]). However, recent studies have shown that the resting heart rate is one of the major indicators of CVD morbidity and mortality in addition to the previously known factors ([@B56]). The occurrence of atherosclerosis, coronary artery disease (CAD), heart failure, hypertension, and stroke are linked with an elevated heart rate, independently of the other CVDs ([@B44]; [@B41]; [@B27]; [@B20], [@B23]; [@B39]).

The occurrences of coronary atherosclerosis in patients that have undergone coronary artery bypass surgery or recurring myocardial infarction have been independently linked to intrinsically elevated heart rate as a result of increasing the mechanical load and tensile strength on the arterial wall and exposure to low endothelial shear stress ([@B20]; [@B46]).

To date, beta blockers, calcium-channel blockers, and other drugs have been utilized to reduce the heart rate either directly or indirectly ([@B51]; [@B40]; [@B54]; [@B61]). These medications have been prescribed for heart failure, angina, and other CVDs. Even though these classes of drugs have irreplaceable use in a myriad of CVDs, they have been claimed to exhibit a lack of selectivity in the reduction of heart rate. They also have additional undesirable side effects and contraindications on the respiratory system, angioedema, metabolism, and other sites.

Taking the limitations of the aforementioned classes of drugs into consideration, researchers have investigated a novel target site called the funny current (*I*~f~) or funny (f) channel, which may be useful for selectively lowering the heart rate. This site in the mammalian sinoatrial node (SAN) has been described as the pacemaker of the heart, and it is activated in phase 4 of the action potential as a result of accelerating diastolic depolarization ([@B61]).

A number of molecules have been identified and developed as *I*~f~ channel blockers, including alinidine (ST-567), cilobradine (DK-AH-269), zatebradine (UL-FS-49), ZD7288 (ICI-D7288), and ivabradine (S-16257-2) (**Figure [1](#F1){ref-type="fig"}**). However, ivabradine (a benzocyclobutene-containing compound) is the only molecule that has passed all of the clinical trial phases and that is used currently as an anti-anginal drug ([@B13]).

![Chemical structures of some "heart-rate-lowering" agents targeting the pacemaker channels of the sinus node.](fphar-08-00874-g001){#F1}

Overall, this novel site has been continuously investigated for the treatment of a variety of CVDs since its identification almost four decades ago. However, several controversies have arisen in the literature from both experimental animal studies and randomized controlled trials, as well as from a meta-analysis on previously developed drugs that target the *I*~f~ channel, particularly ivabradine ([@B10]; [@B39]; [@B66]; [@B16]), even though these drugs have been approved by some regulatory agencies and applied in some countries ([@B36]). Therefore, the aim of this review is to assess the current evidence and progress on targeting the *I*~f~ channel to determine the future direction and challenges for both preventive and therapeutic purposes.

*I*~f~ Channel and Its Role
===========================

In 1979, mammalian SAN cells, a specialized region of the heart, were found to express the funny channel as an inward current triggered on hyperpolarization in the diastolic range of voltages, thus influencing the contraction rate of the entire heart ([@B12]; [@B30]).

The name "funny current" arose because of its numerous unusual characteristics, including the mixed Na^+^ and K^+^ current permeability, activation on hyperpolarization, and slow activation and deactivation kinetics ([@B11]; [@B28]; [@B5]). Studies have shown that the *I*~f~ channel is sensitized at about -100 to -110 mV, and its reversal potential is about -10 to -20 mV, which indicates that it has a mixed permeability to Na^+^ and K^+^. Hence, it is defined as an inward current activated during hyperpolarization at voltages in the range of diastolic depolarization, and it contributes to the generation of rhythmic cardiac activity ([@B11]; [@B40]). Another unusual feature of the *I*~f~ channel is its direct activation by cyclic adenosine monophosphate (cAMP), which activates the opening probability of the *I*~f~ channel, and it is also regulated by voltage-dependent activation ([@B32]). Thus, it is evident that its function, and hence the heart rate, is influenced by the concentration of the second messenger cAMP, which will be increased and decreased by adrenergic and cholinergic stimulation, respectively.

As shown by the overview in **Figure [2](#F2){ref-type="fig"}**, the *I*~f~ activation range (black line in the top left figure) comprises the range of diastolic (pacemaker) potentials (-120 mV to ∼-40 mV), and determines the slope of diastolic depolarization, and hence the rate of the heart, under controlled conditions (black line in the top right figure). Noradrenaline causes stimulation of G proteins by stimulating the β-adrenoreceptors and hence increases the adenylate cyclase activity (red arrow), which in turn increases the intracellular cAMP concentration, and this results in extra activation of *I*~f~ by changing the *I*~f~ activation curve to more positive voltages (red line in top left figure). Thus, more inward current brings about a short diastolic depolarization period, and hence the heart rate speeds up (red line in top right figure) ([@B29]).

![Basic properties of the funny current and its role in autonomic heart rate modulation by up- or down-regulation of cellular cAMP. Elevated cAMP shifts the voltage dependence of the funny channel activation curve to the right, thus increasing current availability during diastole, hence diastolic rate, while the opposite occurs when cAMP is lowered. Ach, acetylcholine; AC, adenylate cyclase; cAMP, cyclic adenosine monophosphate; Gi, inhibitory regulative G-protein; Gs, stimulatory regulative G-protein; β-AR, β-adrenoceptor receptor; NA, noradrenaline; M2-R, type-2 muscarinic receptor (Adapted from [@B29] with permission).](fphar-08-00874-g002){#F2}

Sinoatrial node cells in the myocardium are distinguished by the incidence of a "slow diastolic" phase that produces an impulsive and recurring action potential ([@B28]). Currently, it is generally understood that the generation of the diastolic depolarization is caused by activation of the *I*~f~ channel at the end of an action potential. Therefore, either stimulation or inhibition of the *I*~f~ channel may trigger or suppress the heart beat by altering the diastolic time of depolarization. Hence, the activation of the *I*~f~ channels decreases the diastolic time, which subsequently produces myocardial and associated problems. Alternatively, the inhibition of the *I*~f~ channels increases the diastolic time because of the slower firing of the next action potential and beat. This, in turn, results in improved perfusion of the myocardium and reduces its oxygen demand, which is beneficial for the management and prevention of CAD, heart failure, and other CVDs.

Studies conducted prior to the identification of the *I*~f~ channel concluded that the enhancement of the K^+^ conductance of the pacemaker cells in the SAN due to the discharge of acetylcholine (Ach) slows the heart rate ([@B55]; [@B24]). In addition, an experimental study by [@B58] suggested that K^+^ channels are responsible for the ACh-dependent K^+^ conductance increase in SAN cells, which possess distinct opening and conductance properties compared to atrial and ventricular cells. However, SAN cells have similar properties to the other ACh-activated cells in terms of resting K^+^ current. This study also found an excess of short channel openings, the reason for which was unclear ([@B58]) but could be the occurrence of *I*~f~ channel activation, although it was not considered in this study. After this finding, a study by [@B31] revealed that at low (resting) or moderate vagal activities, ACh-mediated *I*~f~ current inhibition is responsible for the slowing of heart rate, while the K^+^ current is activated by a marked vagal stimulation (high ACh concentration). The result shows in a pronounced decrement of heart rate (bradycardia) in the SAN cells and atrium as well ([@B31]; [@B29]). These findings provide new insights into the mechanism through which the heart rate is decreased upon activation of muscarinic receptors by ACh (green lines, as shown in **Figure [2](#F2){ref-type="fig"}**).

HCN Channel: The Molecular Components of the *I*~f~ Channel
===========================================================

The mammalian hyperpolarization-activated cyclic nucleotide-gated (HCN) channel family consists of four isoforms, namely HCN1--4, which belong to the superfamily of voltage-gated potassium channels and represent the molecular α subunits of the native "funny" channels present in the heart and brain ([@B6]; [@B3],[@B4]; [@B60]). *In vivo* examinations have revealed that functional HCN channels can be produced in homomeric as well as heteromeric tetramers with the exception of HCN2--3 heteromers ([@B3]). The HCN4 isoform is the dominant HCN transcript in human SAN cells, followed by HCN1 and HCN2, although HCN2 is the foremost transcript in ventricles ([@B18]; [@B60]) and its locus has been recognized as a modulator of heart rate in a genome-wide association study ([@B26]).

The physiological role of the HCN family of channels in the central nervous system and heart is enormous ([@B32]; [@B3]), and they are responsible for the *I*~f~ current in the SAN. Six-transmembrane α-helical segments (S1--S6) make up each HCN isoform, with the positively charged S4 domain acting as a voltage sensor in the pore region formed between domains S5 and S6, which acts as a conduction pathway and selectively filters binding. The presence of a glycine--tyrosine--glycine (GYG) sequence, which is typical for the pore-loop region of K^+^-permeable voltage-gated ion channel subunits, has been reported; a linking site for cAMP in the C-terminal region of the peptide is found that binds to the channels, through a direct action on the channel itself but not by phosphorylation, in the cyclic nucleotide-binding domain (CNBD) located within the C-terminus ([@B1]; [@B3]; [@B60]). The binding of cAMP to the HCN channels increases the probability of the channel to be open during hyperpolarization by inducing a conformational change of the protein ([@B60]). Different distinguishing properties of the native *I*~f~ are exhibited by the HCN isoforms, including activation by hyperpolarized membrane potentials, modulation by cAMP, permeability to Na^+^ and K^+^, and the chunk on the part of cesium (Cs^+^) ([@B47]).

The *I*~f~ Channel As An Emerging Therapeutic Target
====================================================

The funny channel is a good target for the development of new drugs as it generates spontaneous activity and controls the heart rate by acting specifically on the cardiac rate control and pacemaker rhythm. Lowering the heart rate under different cardiac conditions is one means of controlling CVDs pharmacologically, even though there are different risk factors ([@B62]).

Various experimental and epidemiological studies have shown that, in spite of the multiple identified risk factors such as hypertension, diabetes, and smoking, an increased resting heart rate is one of the key independent predictors of CAD, heart failure, and cardiovascular mortality ([@B69]; [@B39]; [@B15]). An increased resting heart rate has also been linked to mental stress, which, in turn, aggravates myocardial ischemia in patients with CAD and is considered to be one risk factor for hypertension and atherosclerosis ([@B17]). The consequences of increased heart rate can favor the progression of myocardial ischemia as a result of mounting myocardial oxygen use and decreased coronary blood flow due to reduced diastolic filling time ([@B51]).

In mouse models of hypercholesterolemia and endothelial dysfunction, the administration of ivabradine reduced the levels of vascular oxidative stress markers and atherosclerotic plaque development and restored endothelial function through the inhibition of the *I*~f~ channel ([@B20]). An increased heart rate can cause plaque rupture and associated myocardial problems ([@B33]).

Heart rate during acute ischemia-reperfusion is an important determinant of susceptibility to reperfusion arrhythmias, with a higher heart rate found to cause a predisposition to arrhythmias in rats ([@B8]). [@B8] found that pacing either throughout the experiment or during ischemia alone led to a rate-dependent increase in the occurrence of reperfusion-induced ventricular fibrillation (VF), from 25% in the unpaced hearts to \>90% when the rate was ≥420 beats/min, but pacing during reperfusion alone did not increase the occurrence of reperfusion-induced VF. These data suggest that a clinical therapeutic strategy for heart rate reduction during ischemia-reperfusion may reduce the incidence of reperfusion arrhythmias. However, it remains unclear whether an increased heart rate is associated with ventricular or reperfusion arrhythmia. To investigate this, animal experiments have been performed using ivabradine to evaluate the outcome of selective heart rate reduction during the occurrence of ischemia and reperfusion reduced reperfusion VF. The heart rate reduction as a result of acute ischemia led to a reduction in the occurrence of reperfusion arrhythmias, whereas the heart rate at reperfusion alone did not influence the occurrence of reperfusion VF, as neither a bolus of ivabradine nor pacing prior to reperfusion changed the occurrence of reperfusion VF. Hence, the anti-arrhythmic effects of ivabradine in the heart rate reduction during acute ischemia may be the result of the slower development of ischemia-induced electrophysiological alterations ([@B50]).

All of the phases of the cardiovascular continuum (**Figure [3](#F3){ref-type="fig"}**) from vascular risk factors to cardiovascular episodes and heart failure are essentially influenced by heart rate. Hence, in CVD prevention, heart rate is one of the risk indicators and therapeutic targets ([@B44]; [@B41]; [@B27]; [@B20], [@B22]; [@B39]).

![Pathophysiological effects of heart rate on the cardiovascular disease continuum (Adapted from [@B22] with permission).](fphar-08-00874-g003){#F3}

Patients with chronic stable angina can benefit from decreased heart rate because of the associated improved myocardial perfusion and reduced myocardial oxygen demand. The use-dependence of heart rate reducing agents is one of their distinctive attributes in which the outcome of drug application accumulates through repetitive action ([@B70]). This important drug characteristic was achieved for ivabradine as a result of the accumulated inhibition of *I*~f~ current by the activation/deactivation procedure, which is therapeutically useful and it indicates that the slowing action of the drugs will be stronger at elevated heart rates when the effect of slower heart rate is essential ([@B14]).

According to a study conducted on mice to evaluate the effects of chronic mental stress and heart rate on endothelial function and cerebral ischemia, chronic mental stress impairs the function of endothelial cells, increases vascular and brain oxidative stress, and enlarges the size of cerebral lesions ([@B21]). The endothelial function, oxidative stress, and ischemic brain injury could be restored, reduced, and protected, respectively, by heart rate reduction using ivabradine (10 mg/kg per day), as a result of the reduced activity of NADPH oxidase in the aorta in addition to aortic lipid peroxidation and reduction of the expression of nitric oxide synthase (eNOS). These results suggest that heart rate reduction by *I*~f~ inhibition is a likely new target for improving the cerebrovascular function after ischemic events ([@B21]). In a separate study, [@B72] reported that the chemokine-induced migration of CD4-positive lymphocytes was inhibited upon administration of ivabradine by limiting both phosphatidylinositol 3 kinase (PI3K) activity and the phosphorylation of protein kinase B (AKT).

*I*~f~ Channel Blockers
-----------------------

The previously established drugs for the treatment of angina have undesirable side effects in addition to reducing the heart rate, including the deterioration of peripheral vascular disease, psychological depression, bronchospasm, peripheral vasoconstriction of the extremities, hypotension, leg tiredness, and erectile dysfunction in the case of β-adrenergic blockers and peripheral edema, hypotension, and headache in the case of calcium-channel blockers ([@B62]). Furthermore, the treatment of angina using the conventional therapies is often ineffective, with almost two-thirds of patients experiencing about two angina attacks per week on average ([@B52]). Hence, a selective drug that reduces heart rate, such as ivabradine, will be necessary for some patients because of safety and efficacy issues ([@B42]).

Numerous molecules that block the pacemaker channels have been developed (**Figure [1](#F1){ref-type="fig"}**), including alinidine, cilobradine, zatebradine, ZD7288, and ivabradine, but ivabradine (a benzocyclobutene-containing compound) is the only drug that has completed the full range of clinical trials and is currently marketed as an anti-anginal drug (under the brand name of Corlanor). The development of the other molecules was discontinued for various reasons, for instance, limited channel specificity for alinidine and ZD7288, a lack of substantial inotropic or vascular alterations for cilobradine, and the development of undesirable visual side effects for zatebradine ([@B13]).

The recently developed ivabradine acts specifically on the SAN as a novel selective heart-rate-reducing agent that selectively inhibits *I*~f~ channel binding, a primary SAN pacemaker current, and reduces the heart rate both at rest and during exercise ([@B14]; [@B10]). Ivabradine is currently licensed by the European Medicines Agency and the US Food and Drug Administration for the management of heart failure and stable angina both alone and in combination with other classes of drugs ([@B62]; [@B68]).

Therapeutic Effects of Ivabradine
---------------------------------

The use of ivabradine to selectively reduce heart rate has been investigated in randomized trials such as the BEAUTIFUL and SHIFT trials, and heart rate was found to be an adjustable risk factor in patients with heart failure ([@B39]; [@B63]). In the BEAUTIFUL study, elevated heart rate (≥70 bpm) in patients with CAD and left ventricular dysfunction was a strongly independent risk factor, which was supported by the SHIFT study performed in a cohort of patients with a left ventricular ejection fraction of ≤35% and a heart rate of ≥70 bpm. Ivabradine did not improve the primary composite endpoint in either of these trials, but it was found to be significantly effective in a subgroup analysis of patients with a heart rate of ≥70 bpm and a left ventricular ejection fraction of ≤35%. Accordingly, this drug has been suggested as an add-on therapy in combination with beta blockers for patients with a heart rate of ≥70 bpm and an ejection fraction of ≤35%.

Additional trials have been performed in the search for safe and effective CAD treatments. A 3-month double-blind, multicenter, controlled trial conducted in patients with stable angina indicated that ivabradine treatment led to improved exercise tolerance without pharmacological tolerance or rebound phenomena, dose-dependent decreases in resting and exercising heart rate, a delayed onset of exercise-induced ischemia, and a decreased incidence of ambient angina attacks ([@B10]).

[@B48] performed a study to observe the beneficial effects of delayed ivabradine treatment in severe chronic heart failure in adult male Wistar rats. The results showed that ivabradine led to decreased mRNA and protein levels of cardiac angiotensin-converting enzyme, a marker of the cardiac renin-angiotensin-aldosterone system (RAAS), and angiotensin receptor 1, which indicated that the fibrotic remodeling of the remote myocardium was reduced due to the low level of RAAS activation. Thus, ivabradine allowed cardiac function to be retained after heart failure as a result of its heart-rate-reducing effects ([@B48]). Another study that investigated induced dyslipidemia in the hypercholesterolemic rabbit model revealed that the levels of circulating angiotensin-II and aldosterone were correlated to the heart rate and significantly decreased upon ivabradine treatment ([@B15]).

The effects of ivabradine have also been compared with well-established beta blockers and calcium-channel blockers such as atenolol ([@B65]), metoprolol ([@B7]), and amlodipine ([@B57]) in patients with stable angina or heart failure. These studies revealed ivabradine to have a comparable effectiveness to atenolol, with less myocardial depression, and amlodipine for the treatment of stable angina, although ivabradine increased the total exercise duration over the treatment period and was also associated with an increased time to limiting angina, time to onset of angina, and time to 1 mm ST-segment depression in comparison with amlodipine. Although metoprolol reduced the heart rate, it did not prevent the decline in cardiac function and undesirable remodeling, in spite of a reduction in the inflammatory stress response, whereas ivabradine exhibited additional useful cardiac effects that contribute to preventing heart failure.

The mechanism of the reduction in heart rate mediated by ivabradine through the selective inhibition of the funny channel is different to those of beta blockers and calcium-channel blockers, the two conventionally prescribed anti-anginal drugs. One of the distinct characteristics of ivabradine is that it is not intrinsically voltage-dependent but instead depends on the ion flow pathway across the channel pore, i.e., its inhibition of the funny channel is current dependent ([@B14]). *In vitro* animal models as well as clinical trials have shown that ivabradine selectively inhibits the *I*~f~ channel at very low concentrations that cannot possibly affect the L- and T-type Ca^2+^ channels or delayed outward K^+^ channels ([@B62]).

According to the study conducted by [@B19] in diabetic mice, ivabradine attenuates apoptosis, slows down the expression and action of matrix metalloproteinase 2, and hence improves the cardiac function of the animals. This finding indicates that ivabradine may also benefit diabetic patients.

Cardiac fibrosis formation and progression, where TNF-α plays an important role, is implicated in inflammation, which plays a serious role in heart failure ([@B35]). A number of patients with heart failure may develop cardiac fibrosis and it is well known that myocardial infarction induces cardiac remodeling, including fibrosis of the remote myocardium and myocyte hypertrophy ([@B53]). Based on this concept, [@B37] assessed the antifibrotic activity of ivabradine in rat myocardium in the case of chronic heart failure and the results revealed that ivabradine decreases ventricular interstitial fibrosis. According to [@B7], ivabradine could decrease cardiac fibrosis through the inhibition of inflammatory responses and cardiac apoptosis.

Another study indicated that ivabradine may be a promising agent for the management of patients with viral myocarditis ([@B77]). According to this report, ivabradine inhibited the p38 MAPK pathway, downregulated inflammatory reactions, and reduced collagen expression in mice infected with chronic viral myocarditis induced by coxsackievirus B3, thereby slowing down the progression of viral myocarditis to dilated cardiomyopathy.

Ivabradine is generally well tolerated ([@B64]), but atrial fibrillation ([@B38]; [@B16]), excessive bradycardia ([@B25]; [@B38]; [@B16]), phosphene ([@B67]; [@B38]; [@B16]), drug-related nuisances, and blurry vision ([@B16]) were the prominent side effects reported by the clinical trial patients who withdrew from the studies. Ivabradine is also metabolized by CYP3A4 enzymes and it may possibly interact with enzyme inhibitors such as ketoconazole, erythromycin, diltiazem, or verapamil ([@B76]).

Current Controversies Concerning Ivabradine
-------------------------------------------

Multiple randomized controlled trials have been conducted for ivabradine, such as the BEAUTIFUL, SHIFT, SIGNIFY, and ASSOCIATE studies, which involved different disease conditions (mainly heart failure and stable angina). However, these studies revealed several inconsistencies. Although most of the randomized trials found a positive effect for ivabradine, mainly in terms of treating stable angina for patients with heart rates of [\>]{.ul}70 bpm ([@B10]; [@B57]; [@B39]; [@B66]), the current evidence indicates that the inclusion of ivabradine in the regular background therapy of patients with stable CAD devoid of clinical heart failure did not improve patient outcomes ([@B38]), whereas another study reported the non-inferiority of ivabradine compared with the standard care including beta blockers ([@B65]). This indicates that the evidence remains controversial.

A recent meta-analysis based on randomized trials of stable CAD patients indicated that the non-selective utilization of ivabradine is not supported by attestation and can be linked with adverse effects such as new-onset atrial fibrillation, bradycardia, and drug-related irritation ([@B16]). Therefore, the use of ivabradine for CAD seems to be questionable in terms of the cohort of patients treated and this deserves more rigorous investigation in the future.

A study by [@B72] indicated that ivabradine also inhibits other sites, which suggests another controversy regarding its site of action. This report revealed that ivabradine inhibits the chemokine-induced migration of CD4-positive lymphocytes by limiting both PI3K activity and the phosphorylation of Akt. PI3K/Akt is an important molecule that was found to be down-regulated in type 2 diabetes mellitus in insulin signaling ([@B43]). However, ivabradine has shown inconsistent results in terms of the instruction of the PI3K/Akt transduction lane, in particular, up-regulating eNOS expression independently of the PI3K/Akt pathway ([@B9]). Therefore, the different inhibitory effects of ivabradine require further consideration.

Clinical Relevance of the *I*~f~ Channel
----------------------------------------

The main function of the HCN channels is generating the sinus rhythm and hence controlling the heart rate. Dysfunction in the funny channels would be expected to cause arrhythmic behavior. Mutations of the HCN channel genes and their effects on cardiac function have been investigated by molecular approaches ([@B60]).

Mutations in HCN-2 and HCN-4 were found to slow down the pacemaking activity of the SAN ([@B6]). To date, mutations of the human *I*~f~ channel has been restricted to HCN-4 ([@B59]; [@B45]; [@B34]) or the potassium voltage-gated channel subfamily E member 2 (KCNE2), also known as minK-related peptide 1 (MiRP1), is a protein that is encoded by the *KCNE2* gene on chromosome 21 ([@B49]). Voltage clamp experiments, a technique to measure the ion currents passing through the membranes of excitable cells such as neurons while holding the membrane voltage at a fixed level, were performed on wild-type and mutant human HCN-4 channels expressed in Chinese hamster ovary (COS-7) cells, *Xenopus* oocytes, or human embryonic kidney (HEK-293) cells and revealed modifications in the appearance or kinetics of mutant HCN-4 channels. However, the extents to which these transformations affect the *I*~f~ channel flowing in a human SAN action potential remains unclear. The HCN-4 mutation caused both inherited sinus bradycardia, death during early embryogenesis, and other rhythmic disturbances in experimental animals, which clearly indicates the relevance of the funny channels in the disturbance of the cardiac rhythm by gene- or cell-based therapeutic approaches ([@B2]).

The experimental evidence on the major outcomes of the loss-of-function mutations in HCN-4 and KCNE2 reveals inconsistencies between the *in vitro* and *in silico* data and the clinically observed data in the *I*~f~ channel in terms of the action potential and current flow under both exercise and resting conditions, which points to possibilities for future research ([@B71]). In general, HCN-4 and to a lesser extent HCN-2 are the predominant components of the *I*~f~ channel and may lead to future applications in the treatment of rhythmic disturbances, replacing the current approach of using electronic devices with the use of cell/gene-based therapy to deliver the correct genes that encode the *I*~f~ channels.

Conclusion
==========

Multiple studies have demonstrated that atherosclerosis, heart failure, CAD, stroke, and arrhythmia are self-regulating prognosticators of CVDs as a result of an elevated heart rate. Even though randomized clinical trials have presented some controversies regarding the clinical use of ivabradine for CAD, the drug provides a safe and effective means to reduce heart rate, either alone or in combination with the already existing drugs, by selectively inhibiting the *I*~f~ channel without significantly affecting the action potential, inotropic activity, or ventricular contractility of the heart and with minimal adverse effects. Currently, funny channel inhibition is being targeted for the treatment and prevention of CVDs such as atherosclerosis and stroke.

Future Perspectives
===================

Based on the available evidence and the prospect of *I*~f~ channel targeting; it is very apparent that inhibition of this channel can be used for the prevention and treatment of cardiovascular-related mortality and morbidity. Through this strategy, it seems plausible to reduce CVD morbidity and mortality by an early screening of the at-risk population by measuring the simple vital sign of resting heart rate and providing a long-acting dosage form of the current oral or intravenous *I*~f~ inhibitors. Furthermore, the *I*~f~ channel has recently been investigated for the prevention and treatment of stroke, hypertension, atherosclerosis, myocardial infarction, and arrhythmia; fortunately, all of the *in vitro* studies and animal models showed positive findings. It is also suggested that the use of cell/gene-based therapy for the *in situ* delivery of the genes that encode the *I*~f~ channel might represent a future treatment strategy for rhythmic disturbances, which could replace the current practice of using electronic devices. Hence, in the future, *I*~f~ channel inhibitors might be clinically useful for prevention and treatment of these disorders.
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